Lars Henrik Jensen

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 2.8K citations · Full text

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim et al. · The Lancet Oncology · 2022 · 818 citations · Full text

Medicine, Immunology, Pathology +9

High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study

Ane Appelt, John Pløen, Henrik Harling et al. · The Lancet Oncology · 2015 · 539 citations

Surgical Oncology, Radiation Therapy, Gastrointestinal Oncology +10

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial

Alexander Stein, Dirk Arnold, John Bridgewater et al. · BMC Cancer · 2015 · 226 citations · Full text

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Thierry André, Mayur M. Amonkar, Josephine M. Norquist et al. · The Lancet Oncology · 2021 · 211 citations

Health-related Quality, Medicine, Cancer Management +5